News coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of -1.00 on their scale. InfoTrie also assigned media stories about the specialty pharmaceutical company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected ANI Pharmaceuticals’ ranking:
- ANI Pharmaceuticals Inc (ANIP) Q1 2019 Earnings Call Transcript (finance.yahoo.com)
- Somewhat Negative Press Coverage Extremely Likely to Impact ANI Pharmaceuticals (ANIP) Share Price (americanbankingnews.com)
- ANI Pharmaceuticals (ANIP) Stock Rating Lowered by Raymond James (americanbankingnews.com)
- Edited Transcript of ANIP earnings conference call or presentation 9-May-19 2:30pm GMT (finance.yahoo.com)
- ANI Pharmaceuticals Inc. (ANIP) CEO Arthur Przybyl on Q1 2019 Results – Earnings Call Transcript (seekingalpha.com)
NASDAQ:ANIP opened at $73.19 on Friday. ANI Pharmaceuticals has a 12 month low of $36.92 and a 12 month high of $74.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 0.92 and a quick ratio of 0.68. The stock has a market capitalization of $867.14 million, a PE ratio of 15.88 and a beta of 2.37.
Several equities research analysts have recently commented on the stock. Raymond James cut shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and raised their target price for the stock from $73.00 to $82.00 in a research report on Friday. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a research report on Thursday. BidaskClub raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 7th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $79.25.
In related news, SVP Robert W. Schrepfer sold 4,651 shares of the stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total value of $299,663.93. Following the completion of the transaction, the senior vice president now directly owns 53,484 shares in the company, valued at approximately $3,445,974.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Arthur Przybyl sold 27,625 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total transaction of $1,755,016.25. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/somewhat-negative-press-coverage-extremely-likely-to-impact-ani-pharmaceuticals-anip-stock-price.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Recommended Story: Why is the conference call important?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.